Akebia Therapeutics: Kidney Diseases trials

The registry lists 29 Kidney Diseases studies with Akebia Therapeutics as lead sponsor. 0 are open to participants now and 23 have results posted.

Phase 1 1Phase 2 13Phase 3 12Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsCompletedNCT04707768Phase 3Results posted
• Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4CompletedNCT04707573Phase 2Results posted
• Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin AlfaCompletedNCT03799627Phase 2Results posted
• KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)CompletedNCT03236246Phase 4Results posted
• A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by AlbuminuriaCompletedNCT03217591Phase 2Results posted
• Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating AgentsTerminatedNCT03140722Phase 2Results posted
• Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)CompletedNCT03054350Phase 2Results posted
• Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT03054337Phase 2Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02892149Phase 3Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)CompletedNCT02865850Phase 3Results posted
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)CompletedNCT02680574Phase 3Results posted
• KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKDCompletedNCT02268994Phase 3Results posted
• 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic HemodialysisCompletedNCT02260193Phase 2Results posted
• A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency AnemiaCompletedNCT02128074Phase 2Results posted
• 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01906489Phase 2Results posted
• Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on DialysisCompletedNCT01736397Phase 2Results posted
• A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on DialysisCompletedNCT01554982Phase 3Results posted
• 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01381094Phase 2Results posted
• Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and AnemiaCompletedNCT01235936Phase 2Results posted
• A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal DiseaseCompletedNCT01074125Phase 3Results posted
• Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal DiseaseCompletedNCT00967993Results posted
• A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)CompletedNCT00648167Phase 2Results posted
• Effect of Sulodexide in Early Diabetic NephropathyCompletedNCT00130208Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsWithdrawnNCT05082584Phase 3
• Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseWithdrawnNCT05082571Phase 3
• Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney DiseaseCompletedNCT03992066Phase 1
• Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)WithdrawnNCT03242967Phase 3
• Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong KongTerminatedNCT00462202Phase 3
• Effect of Sulodexide in Overt Diabetic NephropathyTerminatedNCT00130312Phase 4